Early profit takers out today. The recent run up in the pps does not appear to have been due to manipulation. Stay the course the market sentiment toward risky FDA stocks is positive!
JMO!
UEEC has already met these rigorous standards
Quality and Compliance Considerations
1. Stricter Manufacturing Oversight
A focus on public health and corporate accountability could result in:

More frequent inspections of pharmaceutical and medical device manufacturing facilities.

Enhanced compliance with Good Manufacturing Practices (GMP) and Quality System Regulations (QSR).

Stricter enforcement of supply chain transparency, especially for international suppliers.

Companies should evaluate their quality management systems (QMS) to ensure they meet these potential new requirements.

https://www.prp-us.com/quality-compliance-blog/rfkjr